Need help finding what you are looking for?
Contact Us
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2020270
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2020270
Cancer Diagnostics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
PUBLISHED:
PAGES: 130 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Growth Factors of cancer diagnostics Market
The global cancer diagnostics market is witnessing robust growth due to the rising burden of cancer, technological advancements in diagnostics, and increasing government initiatives promoting early detection. According to recent data, the market size was valued at USD 17.24 billion in 2025, and it is projected to reach USD 18.51 billion in 2026. By 2034, the market is expected to expand significantly to USD 38.27 billion, exhibiting a CAGR of 9.5% from 2026 to 2034.
Market Drivers
The increasing prevalence of cancers such as breast, colorectal, and prostate cancer is a primary driver fueling the demand for effective diagnostics. For instance, as per the World Health Organization (WHO), global new cancer cases are projected to reach 35 million by 2050, a 77% increase from 20 million in 2022. Early and precise diagnosis plays a critical role in reducing mortality rates, which has accelerated the adoption of advanced diagnostic solutions, including immunohistochemistry (IHC), in-situ hybridization (ISH), molecular diagnostics, and liquid biopsies.
Government and private organizations have increased initiatives to raise awareness regarding early cancer detection. Programs such as Against Colorectal Cancer in Our Neighborhoods (ACCION) in the U.S., Bowel Cancer Screening Programme (BCSP) in the U.K., and WHO's Global Strategy for Cervical Cancer Elimination aim to expand screening and early intervention efforts. These initiatives are boosting market growth by promoting diagnostic adoption.
Market Restraints
Despite growth, high costs and certain risks associated with diagnostic procedures remain challenges. For example, colonoscopy, a gold standard for colorectal cancer screening, carries risks like bleeding, perforation, and device-associated infections. Additionally, advanced diagnostic instruments such as PCR machines can range from USD 3,000 to USD 30,000, with ongoing maintenance costs, which limits adoption, especially in emerging markets.
Market Opportunities
Emerging markets in Asia Pacific are presenting lucrative opportunities for growth due to increasing government investment in healthcare infrastructure and rising awareness about telemedicine. The COVID-19 pandemic accelerated telemedicine adoption, enabling cancer screening and consultations remotely. This trend is expected to continue, providing access to underserved populations for early diagnosis and follow-ups.
Market Trends
Market players are increasingly focusing on product launches, technological advancements, and partnerships. Notable developments include:
- June 2022: F. Hoffmann-La Roche Ltd launched BenchMark ULTRA PLUS to enhance timely cancer diagnosis.
- October 2023: Partnership between F. Hoffmann-La Roche Ltd, Ibex Medical Analytics, and Amazon Web Services to expand AI-powered diagnostic tools for prostate and blood cancers.
- April 2024: Novelna, a U.S.-based biotech company, developed a blood protein test capable of detecting 18 early-stage cancers with high accuracy.
- May 2023: Pfizer Inc. and Thermo Fisher Scientific Inc. collaborated to enhance accessibility to NGS-based cancer diagnostics in over 30 countries.
- April 2024: Bio-Rad Laboratories, Inc. launched the ddPLEX ESR1 Mutation Detection Kit for biomarker-based diagnostics.
Segmentation Analysis
By Product:
- Assay kits & reagents dominate with 83.07% market share in 2026 due to the increasing number of diagnostic tests and new product launches.
- Instruments are projected to grow steadily, driven by rising healthcare expenditures.
By Technique:
- Immunoassays lead the market due to their efficacy in diagnosing breast, prostate, and other cancers.
- IHC is anticipated to grow fastest, supported by precise diagnosis and treatment prediction capabilities.
By Type:
- Tissue biopsy dominates with 87.04% market share in 2026, attributed to high accuracy and detailed molecular profiling.
- Liquid biopsy is growing fastest due to faster result output, often 26.8 days quicker than tissue biopsies.
By Cancer Type:
- Breast cancer segment remains dominant, reflecting the high global burden.
- Lung cancer is growing rapidly due to increasing smoking prevalence among youth.
By End-user:
- Clinical laboratories dominate the market due to high testing volumes and technologically advanced equipment.
- Hospitals & clinics are also expanding, offering both diagnosis and treatment at the same location.
Regional Outlook
- North America dominated in 2025 with 36.81% market share (USD 6.35 billion), projected to reach USD 6.9 billion in 2026, driven by companies like Thermo Fisher Scientific, Abbott, Illumina, and GE Healthcare.
- Europe contributed USD 5.28 billion in 2025, reaching USD 5.63 billion in 2026, supported by partnerships and genome projects like the 100,000 Genomes Project.
- Asia Pacific grew to USD 3.78 billion in 2025, projected at USD 4.07 billion in 2026, with rising cancer burden in countries like China, Japan, and India.
- Latin America and Middle East & Africa are smaller but growing markets, valued at USD 1.13 billion and USD 0.69 billion in 2025, respectively.
Competitive Landscape
Key players like F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott, Illumina, Inc., GE Healthcare, BD, bioMerieux SA, Myriad Genetics, Inc., Bio-Rad Laboratories, Inc., and QIAGEN dominate the market. Strategic partnerships, product launches, and technological innovations drive growth and expand market access.
Conclusion
The global cancer diagnostics market is poised for strong growth, reaching USD 38.27 billion by 2034. Increasing cancer prevalence, early detection initiatives, technological advancements, and regional expansion in emerging markets are key growth drivers. Despite challenges such as high costs and limited access in some regions, the market continues to evolve with AI integration, biomarker development, and personalized medicine, offering opportunities for improved patient outcomes worldwide.
Segmentation By Product
- Instruments
- Assay Kits & Reagents
By Technique
- Immunohistochemistry (IHC)
- Immunoassays
- Molecular Diagnostics
- Next Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- In-situ Hybridization (ISH)
- Others
- Others
By Type
- Tissue Biopsy
- Liquid Biopsy
By Cancer Type
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
By End-user
- Hospitals & Clinics
- Clinical Laboratories
- Others
By Region
- North America (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country)
- U.S.
- Canada
- Europe (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country/Sub-region)
- U.K.
- Germany
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country/Sub-region)
- Japan
- China
- Australia
- India
- Southeast Asia
- Rest of Asia Pacific
- Latin America (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country/Sub-region)
- South Africa
- GCC
- Rest of the Middle East & Africa
Product Code: FBI110706
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Prevalence of Key Cancer, by Countries/Region in 2025
- 4.2. New Product Launches by Key Players
- 4.3. Recent Industry Developments - Mergers & Acquisitions
- 4.4. Overview of Healthcare Expenditure by Key Countries
- 4.5. Technological Advancements, Diagnostic Instruments & Kits
- 4.6. Impact of COVID-19 on the Cancer Diagnostics Market
5. Global Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Product
- 5.1.1. Instruments
- 5.1.2. Assay Kits & Reagents
- 5.2. Market Analysis, Insights and Forecast - By Technique
- 5.2.1. Immunohistochemistry (IHC)
- 5.2.2. Immunoassays
- 5.2.3. Molecular Diagnostics
- 5.2.3.1. Next Generation Sequencing (NGS)
- 5.2.3.2. Polymerase Chain Reaction (PCR)
- 5.2.3.3. In-situ Hybridization (ISH)
- 5.2.3.4. Others
- 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast - By Type
- 5.3.1. Tissue Biopsy
- 5.3.2. Liquid Biopsy
- 5.4. Market Analysis, Insights and Forecast - By Cancer Type
- 5.4.1. Lung Cancer
- 5.4.2. Breast Cancer
- 5.4.3. Colorectal Cancer
- 5.4.4. Prostate Cancer
- 5.4.5. Others
- 5.5. Market Analysis, Insights and Forecast - By End User
- 5.5.1. Hospitals & Clinics
- 5.5.2. Clinical Laboratories
- 5.5.3. Others
- 5.6. Market Analysis, Insights and Forecast - By Geography
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa
6. North America Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Product
- 6.1.1. Instruments
- 6.1.2. Assay Kits & Reagents
- 6.2. Market Analysis, Insights and Forecast - By Technique
- 6.2.1. Immunohistochemistry (IHC)
- 6.2.2. Immunoassays
- 6.2.3. Molecular Diagnostics
- 6.2.3.1. Next Generation Sequencing (NGS)
- 6.2.3.2. Polymerase Chain Reaction (PCR)
- 6.2.3.3. In-situ Hybridization (ISH)
- 6.2.3.4. Others
- 6.2.4. Others
- 6.3. Market Analysis, Insights and Forecast - By Type
- 6.3.1. Tissue Biopsy
- 6.3.2. Liquid Biopsy
- 6.4. Market Analysis, Insights and Forecast - By Cancer Type
- 6.4.1. Lung Cancer
- 6.4.2. Breast Cancer
- 6.4.3. Colorectal Cancer
- 6.4.4. Prostate Cancer
- 6.4.5. Others
- 6.5. Market Analysis, Insights and Forecast - By End User
- 6.5.1. Hospitals & Clinics
- 6.5.2. Clinical Laboratories
- 6.5.3. Others
- 6.6. Market Analysis, Insights and Forecast - By Country
- 6.6.1. U.S.
- 6.6.2. Canada
7. Europe Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Product
- 7.1.1. Instruments
- 7.1.2. Assay Kits & Reagents
- 7.2. Market Analysis, Insights and Forecast - By Technique
- 7.2.1. Immunohistochemistry (IHC)
- 7.2.2. Immunoassays
- 7.2.3. Molecular Diagnostics
- 7.2.3.1. Next Generation Sequencing (NGS)
- 7.2.3.2. Polymerase Chain Reaction (PCR)
- 7.2.3.3. In-situ Hybridization (ISH)
- 7.2.3.4. Others
- 7.2.4. Others
- 7.3. Market Analysis, Insights and Forecast - By Type
- 7.3.1. Tissue Biopsy
- 7.3.2. Liquid Biopsy
- 7.4. Market Analysis, Insights and Forecast - By Cancer Type
- 7.4.1. Lung Cancer
- 7.4.2. Breast Cancer
- 7.4.3. Colorectal Cancer
- 7.4.4. Prostate Cancer
- 7.4.5. Others
- 7.5. Market Analysis, Insights and Forecast - By End User
- 7.5.1. Hospitals & Clinics
- 7.5.2. Clinical Laboratories
- 7.5.3. Others
- 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 7.6.1. U.K.
- 7.6.2. Germany
- 7.6.3. France
- 7.6.4. Spain
- 7.6.5. Italy
- 7.6.6. Scandinavia
- 7.6.7. Rest of Europe
8. Asia Pacific Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Product
- 8.1.1. Instruments
- 8.1.2. Assay Kits & Reagents
- 8.2. Market Analysis, Insights and Forecast - By Technique
- 8.2.1. Immunohistochemistry (IHC)
- 8.2.2. Immunoassays
- 8.2.3. Molecular Diagnostics
- 8.2.3.1. Next Generation Sequencing (NGS)
- 8.2.3.2. Polymerase Chain Reaction (PCR)
- 8.2.3.3. In-situ Hybridization (ISH)
- 8.2.3.4. Others
- 8.2.4. Others
- 8.3. Market Analysis, Insights and Forecast - By Type
- 8.3.1. Tissue Biopsy
- 8.3.2. Liquid Biopsy
- 8.4. Market Analysis, Insights and Forecast - By Cancer Type
- 8.4.1. Lung Cancer
- 8.4.2. Breast Cancer
- 8.4.3. Colorectal Cancer
- 8.4.4. Prostate Cancer
- 8.4.5. Others
- 8.5. Market Analysis, Insights and Forecast - By End User
- 8.5.1. Hospitals & Clinics
- 8.5.2. Clinical Laboratories
- 8.5.3. Others
- 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. Australia
- 8.6.4. India
- 8.6.5. Southeast Asia
- 8.6.6. Rest of Asia Pacific
9. Latin America Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Product
- 9.1.1. Instruments
- 9.1.2. Assay Kits & Reagents
- 9.2. Market Analysis, Insights and Forecast - By Technique
- 9.2.1. Immunohistochemistry (IHC)
- 9.2.2. Immunoassays
- 9.2.3. Molecular Diagnostics
- 9.2.3.1. Next Generation Sequencing (NGS)
- 9.2.3.2. Polymerase Chain Reaction (PCR)
- 9.2.3.3. In-situ Hybridization (ISH)
- 9.2.3.4. Others
- 9.2.4. Others
- 9.3. Market Analysis, Insights and Forecast - By Type
- 9.3.1. Tissue Biopsy
- 9.3.2. Liquid Biopsy
- 9.4. Market Analysis, Insights and Forecast - By Cancer Type
- 9.4.1. Lung Cancer
- 9.4.2. Breast Cancer
- 9.4.3. Colorectal Cancer
- 9.4.4. Prostate Cancer
- 9.4.5. Others
- 9.5. Market Analysis, Insights and Forecast - By End User
- 9.5.1. Hospitals & Clinics
- 9.5.2. Clinical Laboratories
- 9.5.3. Others
- 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 9.6.1. Brazil
- 9.6.2. Mexico
- 9.6.3. Rest of Latin America
10. Middle East & Africa Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Product
- 10.1.1. Instruments
- 10.1.2. Assay Kits & Reagents
- 10.2. Market Analysis, Insights and Forecast - By Technique
- 10.2.1. Immunohistochemistry (IHC)
- 10.2.2. Immunoassays
- 10.2.3. Molecular Diagnostics
- 10.2.3.1. Next Generation Sequencing (NGS)
- 10.2.3.2. Polymerase Chain Reaction (PCR)
- 10.2.3.3. In-situ Hybridization (ISH)
- 10.2.3.4. Others
- 10.2.4. Others
- 10.3. Market Analysis, Insights and Forecast - By Type
- 10.3.1. Tissue Biopsy
- 10.3.2. Liquid Biopsy
- 10.4. Market Analysis, Insights and Forecast - By Cancer Type
- 10.4.1. Lung Cancer
- 10.4.2. Breast Cancer
- 10.4.3. Colorectal Cancer
- 10.4.4. Prostate Cancer
- 10.4.5. Others
- 10.5. Market Analysis, Insights and Forecast - By End User
- 10.5.1. Hospitals & Clinics
- 10.5.2. Clinical Laboratories
- 10.5.3. Others
- 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 10.6.1. South Africa
- 10.6.2. GCC
- 10.6.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Profiles of Players Operating in the Market
- 11.2.1. F. Hoffmann-La Roche Ltd
- 11.2.1.1. Overview
- 11.2.1.2. Products & services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Thermo Fisher Scientific Inc.
- 11.2.2.1. Overview
- 11.2.2.2. Products & services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Abbott
- 11.2.3.1. Overview
- 11.2.3.2. Products & services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Illumina, Inc.
- 11.2.4.1. Overview
- 11.2.4.2. Products & services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. GE Healthcare
- 11.2.5.1. Overview
- 11.2.5.2. Products & services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. BD
- 11.2.6.1. Overview
- 11.2.6.2. Products & services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. bioMerieux SA
- 11.2.7.1. Overview
- 11.2.7.2. Products & services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Myriad Genetics, Inc
- 11.2.8.1. Overview
- 11.2.8.2. Products & services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Bio-Rad Laboratories, Inc.
- 11.2.9.1. Overview
- 11.2.9.2. Products & services
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.10. QIAGEN
- 11.2.10.1. Overview
- 11.2.10.2. Products & services
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. Financials (Based on Availability)
- 11.2.1. F. Hoffmann-La Roche Ltd
Product Code: FBI110706
List of Tables
- Table 1: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
- Table 2: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
- Table 3: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
- Table 4: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 5: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
- Table 6: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
- Table 7: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 8: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
- Table 9: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
- Table 10: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
- Table 11: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 12: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
- Table 13: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
- Table 14: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 15: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
- Table 16: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
- Table 17: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
- Table 18: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 19: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
- Table 20: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
- Table 21: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 22: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
- Table 23: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
- Table 24: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
- Table 25: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 26: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
- Table 27: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
- Table 28: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 29: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
- Table 30: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
- Table 31: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
- Table 32: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 33: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
- Table 34: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
- Table 35: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 36: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
- Table 37: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
- Table 38: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
- Table 39: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 40: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
- Table 41: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
- Table 42: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Cancer Diagnostics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Cancer Diagnostics Market Value Share (%), by Product, 2025 & 2034
- Figure 3: Global Cancer Diagnostics Market Value Share (%), by Technique, 2025 & 2034
- Figure 4: Global Cancer Diagnostics Market Value Share (%), by Type, 2025 & 2034
- Figure 5: Global Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025 & 2034
- Figure 6: Global Cancer Diagnostics Market Value Share (%), by End-user, 2025 & 2034
- Figure 7: Global Cancer Diagnostics Market Value (USD billion), by Region, 2025 & 2034
- Figure 8: North America Cancer Diagnostics Market Value (USD billion), by Product, 2025 & 2034
- Figure 9: North America Cancer Diagnostics Market Value Share (%), by Product, 2025
- Figure 10: North America Cancer Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
- Figure 11: North America Cancer Diagnostics Market Value Share (%), by Technique, 2025
- Figure 12: North America Cancer Diagnostics Market Value (USD billion), by Type, 2025 & 2034
- Figure 13: North America Cancer Diagnostics Market Value Share (%), by Type, 2025
- Figure 14: North America Cancer Diagnostics Market Value (USD billion), by Cancer Type, 2025 & 2034
- Figure 15: North America Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025
- Figure 16: North America Cancer Diagnostics Market Value (USD billion), by End-user, 2025 & 2034
- Figure 17: North America Cancer Diagnostics Market Value Share (%), by End-user, 2025
- Figure 18: North America Cancer Diagnostics Market Value (USD billion), By Country, 2025 & 2034
- Figure 19: North America Cancer Diagnostics Market Value Share (%), By Country, 2025
- Figure 20: Europe Cancer Diagnostics Market Value (USD billion), by Product, 2025 & 2034
- Figure 21: Europe Cancer Diagnostics Market Value Share (%), by Product, 2025
- Figure 22: Europe Cancer Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
- Figure 23: Europe Cancer Diagnostics Market Value Share (%), by Technique, 2025
- Figure 24: Europe Cancer Diagnostics Market Value (USD billion), by Type, 2025 & 2034
- Figure 25: Europe Cancer Diagnostics Market Value Share (%), by Type, 2025
- Figure 26: Europe Cancer Diagnostics Market Value (USD billion), by Cancer Type, 2025 & 2034
- Figure 27: Europe Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025
- Figure 28: Europe Cancer Diagnostics Market Value (USD billion), by End-user, 2025 & 2034
- Figure 29: Europe Cancer Diagnostics Market Value Share (%), by End-user, 2025
- Figure 30: Europe Cancer Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 31: Europe Cancer Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
- Figure 32: Asia Pacific Cancer Diagnostics Market Value (USD billion), by Product, 2025 & 2034
- Figure 33: Asia Pacific Cancer Diagnostics Market Value Share (%), by Product, 2025
- Figure 34: Asia Pacific Cancer Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
- Figure 35: Asia Pacific Cancer Diagnostics Market Value Share (%), by Technique, 2025
- Figure 36: Asia Pacific Cancer Diagnostics Market Value (USD billion), by Type, 2025 & 2034
- Figure 37: Asia Pacific Cancer Diagnostics Market Value Share (%), by Type, 2025
- Figure 38: Asia Pacific Cancer Diagnostics Market Value (USD billion), by Cancer Type, 2025 & 2034
- Figure 39: Asia Pacific Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025
- Figure 40: Asia Pacific Cancer Diagnostics Market Value (USD billion), by End-user, 2025 & 2034
- Figure 41: Asia Pacific Cancer Diagnostics Market Value Share (%), by End-user, 2025
- Figure 42: Asia Pacific Cancer Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 43: Asia Pacific Cancer Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
- Figure 44: Latin America Cancer Diagnostics Market Value (USD billion), by Product, 2025 & 2034
- Figure 45: Latin America Cancer Diagnostics Market Value Share (%), by Product, 2025
- Figure 46: Latin America Cancer Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
- Figure 47: Latin America Cancer Diagnostics Market Value Share (%), by Technique, 2025
- Figure 48: Latin America Cancer Diagnostics Market Value (USD billion), by Type, 2025 & 2034
- Figure 49: Latin America Cancer Diagnostics Market Value Share (%), by Type, 2025
- Figure 50: Latin America Cancer Diagnostics Market Value (USD billion), by Cancer Type, 2025 & 2034
- Figure 51: Latin America Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025
- Figure 52: Latin America Cancer Diagnostics Market Value (USD billion), by End-user, 2025 & 2034
- Figure 53: Latin America Cancer Diagnostics Market Value Share (%), by End-user, 2025
- Figure 54: Latin America Cancer Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 55: Latin America Cancer Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
- Figure 56: Middle East & Africa Cancer Diagnostics Market Value (USD billion), by Product, 2025 & 2034
- Figure 57: Middle East & Africa Cancer Diagnostics Market Value Share (%), by Product, 2025
- Figure 58: Middle East & Africa Cancer Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
- Figure 59: Middle East & Africa Cancer Diagnostics Market Value Share (%), by Technique, 2025
- Figure 60: Middle East & Africa Cancer Diagnostics Market Value (USD billion), by Type, 2025 & 2034
- Figure 61: Middle East & Africa Cancer Diagnostics Market Value Share (%), by Type, 2025
- Figure 62: Middle East & Africa Cancer Diagnostics Market Value (USD billion), by Cancer Type, 2025 & 2034
- Figure 63: Middle East & Africa Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025
- Figure 64: Middle East & Africa Cancer Diagnostics Market Value (USD billion), by End-user, 2025 & 2034
- Figure 65: Middle East & Africa Cancer Diagnostics Market Value Share (%), by End-user, 2025
- Figure 66: Middle East & Africa Cancer Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 67: Middle East & Africa Cancer Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
- Figure 68: Global Cancer Diagnostics Market Share (%), By Company, 2025
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.